PMID- 14993777
OWN - NLM
STAT- MEDLINE
DCOM- 20040928
LR  - 20190819
IS  - 1346-9843 (Print)
IS  - 1346-9843 (Linking)
VI  - 68
IP  - 3
DP  - 2004 Mar
TI  - Epoprostenol therapy decreases elevated circulating levels of monocyte 
      chemoattractant protein-1 in patients with primary pulmonary hypertension.
PG  - 227-31
AB  - BACKGROUND: Primary pulmonary hypertension (PPH) is a rare disease characterized 
      by progressively increased resistance of the pulmonary arteries associated with 
      vascular remodeling. Infiltration of inflammatory cells in affected vessels is a 
      common pathological finding. Monocyte chemoattractant protein-1 (MCP-1) is 
      recognized as a potent chemotactic and activating factor for monocytes and 
      leukocytes, but its significance in PPH is unclear. METHODS AND RESULTS: Serum 
      MCP-1 concentrations were measured in 16 PPH patients and the results were 
      compared with those in 16 normal controls. MCP-1 concentrations in PPH patients 
      (265.6+/-29.5 pg/ml) were significantly elevated compared with those in normal 
      controls (119.6+/-6.9 pg/ml, p<0.0001). In 9 patients (3 men, 6 women; mean age, 
      29+/-3 years), repeated MCP-1 and hemodynamic measurements were performed prior 
      to and during intravenous epoprostenol therapy. During a mean follow-up period of 
      7+/-1 months, MCP-1 concentrations were significantly reduced (288.8+/-122.8 to 
      185.9+/-117.5 pg/ml, p<0.01). CONCLUSIONS: Circulating MCP-1 concentrations are 
      increased in PPH patients, but can alleviated by chronic intravenous epoprostenol 
      therapy. The increase in MCP-1 might be one of the important factors responsible 
      for the disease development in patients with PPH.
FAU - Katsushi, Hashimoto
AU  - Katsushi H
AD  - Department of Cardiovascular Medicine, Okayama University Graduate School of 
      Medicine and Dentistry, Japan. khashi@cc.okayama-u.ac.jp
FAU - Kazufumi, Nakamura
AU  - Kazufumi N
FAU - Hideki, Fujio
AU  - Hideki F
FAU - Katsumasa, Miyaji
AU  - Katsumasa M
FAU - Hiroshi, Morita
AU  - Hiroshi M
FAU - Kengo, Kusano
AU  - Kengo K
FAU - Hiroshi, Date
AU  - Hiroshi D
FAU - Nobuyoshi, Shimizu
AU  - Nobuyoshi S
FAU - Tetsuro, Emori
AU  - Tetsuro E
FAU - Hiromi, Matsubara
AU  - Hiromi M
FAU - Tohru, Ohe
AU  - Tohru O
LA  - eng
PT  - Journal Article
PL  - Japan
TA  - Circ J
JT  - Circulation journal : official journal of the Japanese Circulation Society
JID - 101137683
RN  - 0 (Antihypertensive Agents)
RN  - 0 (Chemokine CCL4)
RN  - 0 (Macrophage Inflammatory Proteins)
RN  - DCR9Z582X0 (Epoprostenol)
SB  - IM
MH  - Adult
MH  - Antihypertensive Agents/*therapeutic use
MH  - Blood Flow Velocity
MH  - Chemokine CCL4
MH  - Epoprostenol/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hypertension, Pulmonary/*blood/drug therapy/physiopathology
MH  - Macrophage Inflammatory Proteins/*blood
MH  - Male
MH  - Pulmonary Artery/physiopathology
MH  - Vascular Resistance
EDAT- 2004/03/03 05:00
MHDA- 2004/09/29 05:00
CRDT- 2004/03/03 05:00
PHST- 2004/03/03 05:00 [pubmed]
PHST- 2004/09/29 05:00 [medline]
PHST- 2004/03/03 05:00 [entrez]
AID - 10.1253/circj.68.227 [doi]
PST - ppublish
SO  - Circ J. 2004 Mar;68(3):227-31. doi: 10.1253/circj.68.227.